Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for irritability and social withdrawal in young adults with autism spectrum disorder
MOH_2018-09-06_003647Phase 2Not yet recruiting
- Sponsor
- ד"ר עדי ארן
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Purified cannabidiol, Placebo and Purified cannabidiol + tetrahydrocannabinol (3 arms). Primary endpoint: Change in Aberrant Behavior Checklist-Irritability Subscale. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on MOH_2018-09-06_003647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-09-06_003647.